Improving AAV Gene Therapy Safety Analysis: Multiplex LAM-PCR Provide New Insights Into AAV Vector Integration

被引：0

作者：

Gil-Farina, Irene ^{[1
]}

Kaeppel, Christine ^{[1
]}

Wilkening, Stefan ^{[1
]}

Lopez-Franco, Esperanza ^{[2
]}

Paneda, Maria Astrid ^{[3
]}

Prieto, Jesus ^{[4
]}

Spronck, Lisa ^{[5
]}

von Kalle, Christof ^{[1
]}

Petry, Harald ^{[5
]}

Gonzalez-Aseguinolaza, Gloria ^{[2
]}

Schmidt, Manfred ^{[1
]}

机构：

[1] NCT DKFZ, Translat Oncol, Heidelberg, Germany

[2] CIMA, Gene Therapy & Hepatol, Pamplona, Spain

[3] DIGNA Biotech SL, Madrid, Spain

[4] Univ Hosp Navarra, Pamplona, Spain

[5] uniQure, Amsterdam, Netherlands

来源：

MOLECULAR THERAPY | 2015年 / 23卷

关键词：

D O I：

10.1016/S1525-0016(16)34273-3

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

664

引用

页码：S264 / S264

页数：1

共 41 条

[31] Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice
Marangoni, Dario
Bush, Ronald A.
Zeng, Yong
Wei, Lisa L.
Ziccardi, Lucia
Vijayasarathy, Camasamudram
Bartoe, Joshua T.
Palyada, Kiran
Santos, Maria
Hiriyanna, Suja
Wu, Zhijian
Colosi, Peter
Sieving, Paul A.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2016, 3
[32] Intravenous Neonatal Gene Therapy Corrects GM2 Gangliosidosis in Sandhoff Mice for Long-Term, By Using AAV Viral Vector Expressing a New Hexosaminidase Variant
Osmon, Karlaina J. L.
Woodley, Evan
Thompson, Patrick
Ong, Katalina
Karumuthil-Melethil, Subha
Mark, Brian
Mahuran, Don
Gray, Steven J.
Walia, Jagdeep S.
MOLECULAR THERAPY, 2015, 23 : S283 - S284
[33] Safety and efficacy of a phase 1 clinical gene therapy trial in patients with advanced heart failure using a rationally designed cardiotropic AAV vector targeting protein phosphatase inhibitor-1
Henry, T. D.
Chung, E.
Alvisi, M.
Sethna, F.
Murray, D.
Traverse, J. H.
Roberts, L.
Roessig, L.
Ervin, L.
Mikhail, S.
Jiang, C.
Samulski, J.
Kranias, E. G.
Tretiakova, A.
Hajjar, R. J.
EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 237 - 238
[34] High Throughput Integration Site Analysis Reveals an Improved Safety Profile of a SIN gammaretroviral vector for X-CGD Gene Therapy
Scholz, S.
Diaz, M.
Stein, S.
Schambach, A.
Glimm, H.
von Kalle, C.
Grez, M.
Schmidt, M.
HUMAN GENE THERAPY, 2011, 22 (10) : A108 - A108
[35] Interim Analysis of Immunogenicity to the Vector Capsid and Transgene - Expressed Human FVIII in a Phase-1/ 2 Clinical Study of Bmn 270, an AAV5-Mediated Gene Therapy for Hemophilia a
Long, Brian
Kim, Benjamin
Wong, Wing Yen
Yang, Ke
Vettermann, Christian
Pryer, Nancy
Hardet, Romain
Kuranda, Klaudia
Veron, Philippe
Mingozzi, Federico
Pierce, Glenn F.
Schweighardt, Becky
BLOOD, 2017, 130
[36] Gene Therapy for Crigler-Najjar Syndrome with AT342, a Liver-Targeted AAV8-UGT1A1 Vector - Preliminary Safety and Efficacy Results from a Phase 1/2 Study (VALENS)
Prasad, Suyash
Strauss, Kevin A.
McKiernan, Patrick
Mazariegos, George
Ovchinsky, Nadia
Dhawan, Anil
Ranganathan, Sarangarajan
Deheragoda, Maesha
Lawlor, Michael W.
Noursalehi, Mojtaba
Kennedy, William P.
MOLECULAR THERAPY, 2018, 26 (05) : 251 - 251
[37] Interim analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII IN a phase-1/2 clinical study of BMN-270, an AAV5 mediated gene therapy for hemophilia A
Long, B.
Kim, B.
Wong, W. Y.
Yang, K.
Vettermann, C.
Pryer, N.
Hardet, R.
Kuranda, K.
Veron, P.
Mingozzi, F.
Pierce, G. F.
Schweighardt, B.
HAEMOPHILIA, 2018, 24 : 60 - 60
[38] Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for haemophilia A
Long, Brian
Robinson, Tara
Day, Jonathan
Yu, Hua
Lau, Kelly
Patton, Kathryn
de Hart, Greg
Henshaw, Josh
Agarwal, Suresh
Vettermann, Christian
Gupta, Soumi
HAEMOPHILIA, 2022, 28 : 23 - 24
[39] Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A
Long, Brian
Fong, Sylvia
Handyside, Britta
Robinson, Tara
Day, Jonathan
Yu, Hua
Lau, Kelly
Patton, Kathryn
de Hart, Greg
Henshaw, Josh
Agarwal, Suresh
Vettermann, Christian
Gupta, Soumi
JOURNAL OF HEPATOLOGY, 2022, 77 : S540 - S540
[40] Human liver biopsy analysis shows decline in FVIII levels following AAV5-hFVIII-SQ gene therapy may be due to low RNA transcription levels despite persistence of full-length episomal vector genomes
Yates, Bridget
Ismail, Ashrafali
Mattis, Aras
Gonzalez, Alyssa
Kim, Chan Kyu
Jayaram, Kala
Kenet, Gili
Mason, Jane
Mahlangu, Johnny
Dunn, Amy
Shapiro, Susan
Wang, Michael
Peyvandi, Flora
Giermasz, Adam
Kazmi, Rashid
Key, Nigel S.
Ozelo, Margareth
Robinson, Tara M.
Fong, Sylvia
HAEMOPHILIA, 2024, 30 : 56 - 58

← 1 2 3 4 5 →